IL288916B2 - Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation - Google Patents

Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation

Info

Publication number
IL288916B2
IL288916B2 IL288916A IL28891621A IL288916B2 IL 288916 B2 IL288916 B2 IL 288916B2 IL 288916 A IL288916 A IL 288916A IL 28891621 A IL28891621 A IL 28891621A IL 288916 B2 IL288916 B2 IL 288916B2
Authority
IL
Israel
Prior art keywords
antigen
muc16
binding
antibody
binding molecule
Prior art date
Application number
IL288916A
Other languages
English (en)
Hebrew (he)
Other versions
IL288916A (en
IL288916B1 (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL288916A publication Critical patent/IL288916A/en
Publication of IL288916B1 publication Critical patent/IL288916B1/en
Publication of IL288916B2 publication Critical patent/IL288916B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/48—Diagnostic techniques
    • A61B6/481—Diagnostic techniques involving the use of contrast agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
    • A61K51/1042—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors against T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Pathology (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL288916A 2019-06-21 2020-06-19 Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation IL288916B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962864960P 2019-06-21 2019-06-21
PCT/US2020/038669 WO2020257604A1 (en) 2019-06-21 2020-06-19 Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation

Publications (3)

Publication Number Publication Date
IL288916A IL288916A (en) 2022-02-01
IL288916B1 IL288916B1 (en) 2025-11-01
IL288916B2 true IL288916B2 (en) 2026-03-01

Family

ID=71842848

Family Applications (2)

Application Number Title Priority Date Filing Date
IL288916A IL288916B2 (en) 2019-06-21 2020-06-19 Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation
IL323844A IL323844A (en) 2019-06-21 2025-10-09 Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4=1bb co-stimulation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL323844A IL323844A (en) 2019-06-21 2025-10-09 Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4=1bb co-stimulation

Country Status (12)

Country Link
US (2) US12091460B2 (cg-RX-API-DMAC10.html)
EP (1) EP3986934A1 (cg-RX-API-DMAC10.html)
JP (2) JP7743314B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220024035A (cg-RX-API-DMAC10.html)
CN (2) CN118453851A (cg-RX-API-DMAC10.html)
AU (1) AU2020294790A1 (cg-RX-API-DMAC10.html)
CA (1) CA3140083A1 (cg-RX-API-DMAC10.html)
IL (2) IL288916B2 (cg-RX-API-DMAC10.html)
MA (1) MA56537A (cg-RX-API-DMAC10.html)
MX (1) MX2021015270A (cg-RX-API-DMAC10.html)
WO (1) WO2020257604A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202108895B (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
EP4308160A4 (en) * 2021-03-18 2025-07-02 Memorial Sloan Kettering Cancer Center METHODS OF TREATING GYNECOLOGICAL CANCER USING COMBINATION THERAPY WITH MULTISPECIFIC ANTI-MUC16 X CD3 ANTIBODIES AND VEGF INHIBITORS
IL315405A (en) * 2022-03-17 2024-11-01 Regeneron Pharma Methods for treating recurrent epithelioid sarcoma using bispecific anti-MUC16 and anti-CD3 antibodies alone or in combination with anti-PD-1 antibodies
JP2025529310A (ja) * 2022-09-06 2025-09-04 ティージェイ バイオファーマ (シャンハイ) カンパニー, リミテッド 多特異性構築物およびその使用
WO2025082777A1 (en) * 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
TW202542187A (zh) * 2023-12-12 2025-11-01 美商再生元醫藥公司 以雙特異性抗muc16x抗cd3抗體單獨或與抗pd-1抗體組合治療子宮內膜癌之方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180112001A1 (en) * 2016-09-23 2018-04-26 Regeneron Pharmaceuticals, Inc. Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof
WO2018114748A1 (en) * 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5428156A (en) 1993-04-02 1995-06-27 Associated Universities, Inc. Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
US11033642B2 (en) 2014-03-19 2021-06-15 Universitat Zurich Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy
CA2949936C (en) * 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
NZ731966A (en) * 2014-10-16 2019-11-29 Univ Melbourne Novel imaging composition and uses thereof
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
RS67792B1 (sr) * 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
JP7125400B2 (ja) 2016-12-19 2022-08-24 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 標的化4-1bb(cd137)アゴニストとの併用療法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180112001A1 (en) * 2016-09-23 2018-04-26 Regeneron Pharmaceuticals, Inc. Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses Thereof
WO2018114748A1 (en) * 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALISON CRAWFORD ET AL,, A MUCIN 16 BISPECIFIC T CELL-ENGAGING ANTIBODY FOR THE TREATMENT OF OVARIAN CANCER, 19 June 2019 (2019-06-19) *
DIMITRIS SKOKOS ET AL,, A CLASS OF COSTIMULATORY CD28-BISPECIFIC ANTIBODIES THAT ENHANCE THE ANTITUMOR ACTIVITY OF CD3-BISPECIFIC ANTIBODIES, 8 January 2020 (2020-01-08) *
JUNZO HAMANISHI ET AL,, PD-1/PD-L1 BLOCKADE IN CANCER TREATMENT: PERSPECTIVES AND ISSUES, 22 February 2016 (2016-02-22) *
YEKU O ET AL,, BISPECIFIC ENGAGER IMMUNOTHERAPY TARGETING THE RETAINED PORTION OF MUC16 (MUC16ECTO) IS EFFICACIOUS AGAINST OVARIAN CANCER, 1 June 2019 (2019-06-01) *

Also Published As

Publication number Publication date
AU2020294790A1 (en) 2021-12-16
MX2021015270A (es) 2022-01-18
IL323844A (en) 2025-12-01
JP7743314B2 (ja) 2025-09-24
KR20220024035A (ko) 2022-03-03
WO2020257604A1 (en) 2020-12-24
MA56537A (fr) 2022-04-27
JP2024164188A (ja) 2024-11-26
ZA202108895B (en) 2023-03-29
US12091460B2 (en) 2024-09-17
IL288916A (en) 2022-02-01
JP2022537269A (ja) 2022-08-25
US20250042999A1 (en) 2025-02-06
CN113993547A (zh) 2022-01-28
IL288916B1 (en) 2025-11-01
EP3986934A1 (en) 2022-04-27
CN118453851A (zh) 2024-08-09
CA3140083A1 (en) 2020-12-24
CN113993547B (zh) 2024-04-26
US20200399371A1 (en) 2020-12-24

Similar Documents

Publication Publication Date Title
ZA202108895B (en) Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
IL289041A (en) Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with co-stimulation of 4-1bb
HUS2500032I1 (hu) Bispecifikus anti-BCMA X anti-CD3 antitestek és azok alkalmazásai
IL268369A (en) Anti-CD3 antibodies, bispecific-antigen-binding compounds that bind CD3 and CD20, and their uses
IL289946A (en) Bispecific antibodies against cd3 and cd20
IL264248A (en) Bispecific binding proteins, antibody-like, binding specifically to CD3 and CD123
EP3889174A4 (en) BISPECIFIC HOMODIMER-TYPE ANTIBODY AGAINST HER2 AND CD3 AND USE THEREOF
IL280002A (en) Antibody molecules that bind CD137 and OX40
SG11202101912UA (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
IL291482A (en) Bispecific antibodies against ceacam5 and cd3
IL276253A (en) Bispecific antigen binding molecules and methods of use
IL250249A0 (en) Molecules that bind bispecifically her2/cd3
PL3559034T3 (pl) Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137)
IL262423A (en) Bispecific constructs binding to cd33 and cd3 for use in the treatment of myeloid leukemia
IL288692A (en) A bispecific antibody against a-syn/igf1r and its use
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
IL280745A (en) Anti-FC epsilon-R1 alpha (FCER1A) antibodies, bispecific antigen-binding molecules that bind FCER1A and CD3, and uses thereof
HK40065364A (en) Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
HK40065365A (en) Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
HK40006696A (en) Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
HK40001468A (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
GB201818281D0 (en) Antibody molecules that bind CD137 and OX40
GB201811407D0 (en) Antibody molecules that bind CD137 and OX40